IOBT · Io Biotech, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $13.74M | $16.65M | $16.38M | - | $20.18M | $15.85M | $14.31M | - | $17.66M | $16.50M |
| SG&A | $5.61M | $6.52M | $6.21M | - | $6.33M | $5.68M | $5.89M | - | $5.83M | $5.35M |
| Total Operating Expenses | $19.36M | $23.17M | $22.58M | - | $26.50M | $21.53M | $20.20M | - | $23.48M | $21.85M |
| D&A | $100.0K | $100.0K | $100.0K | - | $100.0K | $100.0K | $100.0K | - | $100.0K | $100.0K |
| Operating Income | ($19.36M) | ($23.17M) | ($22.58M) | - | ($26.50M) | ($21.53M) | ($20.20M) | - | ($23.48M) | ($21.85M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($1.66M) | $118.0K | $146.0K | - | $209.0K | $374.0K | $415.0K | - | ($439.0K) | $532.0K |
| Net Income | ($8.38M) | ($26.22M) | ($22.42M) | - | ($24.02M) | ($20.69M) | ($19.46M) | - | ($21.68M) | ($21.18M) |
| EPS - Basic | ($0.13) | ($0.40) | ($0.34) | - | ($0.36) | ($0.31) | ($0.30) | - | ($0.43) | ($0.74) |
| EPS - Diluted | ($0.13) | ($0.40) | ($0.34) | - | ($0.36) | ($0.31) | ($0.30) | - | ($0.43) | ($0.74) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.66M | $28.13M | $37.09M | $60.03M | $80.19M | $100.75M | $117.98M | $143.19M | $165.50M | $110.09M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.59M | $5.54M | $5.20M | $4.66M | $5.26M | $5.02M | $3.84M | $3.88M | $6.64M | $4.46M |
| Current Assets | $36.83M | $38.98M | $42.34M | $64.95M | $86.24M | $107.65M | $124.13M | $147.25M | $168.25M | $113.04M |
| Total Assets | $39.96M | $42.33M | $45.74M | $67.70M | $89.94M | $111.47M | $128.16M | $150.72M | $172.55M | $117.56M |
| Current Liabilities | $18.31M | $19.90M | $18.29M | $19.49M | $16.05M | $13.72M | $11.04M | $15.72M | $12.98M | $10.88M |
| Long-term Debt | $16.66M | $6.72M | $0 | $0 | - | - | - | - | - | - |
| Total Liabilities | $39.05M | $40.73M | $19.31M | $20.68M | $17.38M | $15.20M | $12.69M | $17.56M | $14.96M | $13.04M |
| Stockholders' Equity | $911.0K | $1.59M | $26.42M | $47.02M | $72.56M | $96.27M | $115.47M | $133.16M | $157.59M | $104.52M |
| Retained Earnings | ($416.33M) | ($407.95M) | ($381.73M) | ($359.31M) | ($327.98M) | ($303.96M) | ($283.28M) | ($263.82M) | ($237.64M) | ($215.96M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($23.07M) | - | - | - | ($24.93M) | - | - | - |
| Investing Cash Flow | - | - | ($28.0K) | - | - | - | ($11.0K) | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | - | - | - | - |
| CapEx | - | - | $28.0K | - | - | - | $11.0K | - | - | - |
| Free Cash Flow | - | - | ($23.10M) | - | - | - | ($24.94M) | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.03 | - | - | - | 1.28 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -21.0% | -61.9% | -49.0% | - | -26.7% | -18.6% | -15.2% | - | -12.6% | -18.0% |
| Return on equity | -919.6% | -1646.8% | -84.9% | - | -33.1% | -21.5% | -16.9% | - | -13.8% | -20.3% |
| Return on invested capital | -87.0% | -220.2% | -67.5% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.01 | 1.96 | 2.32 | 3.33 | 5.37 | 7.84 | 11.24 | 9.37 | 12.96 | 10.39 |
| Quick ratio | 2.01 | 1.96 | 2.32 | 3.33 | 5.37 | 7.84 | 11.24 | 9.37 | 12.96 | 10.39 |
| Cash ratio | 1.67 | 1.41 | 2.03 | 3.08 | 4.99 | 7.34 | 10.68 | 9.11 | 12.75 | 10.12 |
| Leverage | ||||||||||
| Debt / Equity | 18.29 | 4.22 | 0.00 | 0.00 | - | - | - | - | - | - |
| Debt / Assets | 0.42 | 0.16 | 0.00 | 0.00 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 43.86 | 26.59 | 1.73 | 1.44 | 1.24 | 1.16 | 1.11 | 1.13 | 1.09 | 1.12 |
| Liabilities / Assets | 0.98 | 0.96 | 0.42 | 0.31 | 0.19 | 0.14 | 0.10 | 0.12 | 0.09 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 26.7x | 57.5x | 2.7x | - | 1.0x | 0.8x | 1.0x | - | 0.4x | 0.5x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 27.0% | -7.6% | -11.8% | - | -12.9% | 1.5% | -12.7% | - | -48.0% | -20.3% |
| Net income growth (YoY) | 65.1% | -26.7% | -15.2% | - | -10.8% | 2.3% | -14.2% | - | -38.2% | -14.5% |
| EPS growth (YoY) | 63.9% | -29.0% | -13.3% | - | 16.3% | 58.1% | 50.0% | - | 20.4% | 99.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 7.4% | - | - | - | -68.1% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -98.7% | -98.3% | -77.1% | -64.7% | -54.0% | -7.9% | -7.0% | -4.1% | 2.7% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IO Biotech against the 5 most active filers in the same SIC group.